Lanzhou Biological
a subsidiary of China National Biotec Group (国药集团中国生物), the 30+ year national BoNT incumbent with 5,000+ medical institutions nationwide; 2025-2026 first-in-China indication expansions — primary axillary hyperhidrosis (NMPA approval November 25, 2025) and benign masseter hypertrophy (NMPA approval April 27, 2026,…
- Country
- China
First-in-China axillary hyperhidrosis (Nov 2025) + benign masseter hypertrophy (Apr 2026) NMPA approvals
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant botulinum toxin (biosynthetic Botox) | specialty-fine-chem | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.